Provided by Tiger Trade Technology Pte. Ltd.

iShares Biotechnology ETF

202.93
+0.29000.14%
Post-market: 203.020.0900+0.04%19:37 EDT
Volume:2.29M
Turnover:465.17M
Market Cap:10.28B
PE:32.15
High:205.31
Open:203.94
Low:202.75
Close:202.64
52wk High:217.12
52wk Low:138.79
Shares:50.65M
Float Shares:50.65M
Volume Ratio:1.60
T/O Rate:4.51%
Dividend:0.41
Dividend Rate:0.20%
EPS(TTM):6.31
EPS(LYR):-1.4940
ROE:24.54%
ROA:0.10%
PB:1.26
PE(LYR):-135.83

Loading ...

European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

MT Newswires Live
·
Sep 08

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-09-08

Reuters
·
Sep 08

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

MT Newswires Live
·
Sep 08

Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis

TradingKey
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Dow Drops 438 Points on Losses for Amgen, Salesforce Shares

Dow Jones
·
Sep 08

Amgen Down Nearly 7%, on Pace for Largest Percent Decrease Since March 2020

Dow Jones
·
Sep 08

Argenx Price Target Maintained with a $1150.00/Share by Wedbush

Dow Jones
·
Sep 08

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Rising Oil Prices

MT Newswires Live
·
Sep 08

Amgen-AstraZeneca Cancer Drug Combo Hits Main Survival Goal in Late-Stage Trial

Reuters
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Sector Update: Healthcare

MT Newswires Live
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

TIPRANKS
·
Sep 08

Political and General News Events from September 8

Reuters
·
Sep 08

Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer Effective Sept. 21, 2026

Reuters
·
Sep 08